323579-94-8

Basic information

• Product Name: Benzenemethanol, a-ethenyl-2-nitro-
• CAS NO: 323579-94-8
• Molecular Formula: C9H9NO3
• Molecular Weight: 179.175
• Mol File: 323579-94-8.mol
• Article Data: 16

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, a-ethenyl-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, a-ethenyl-2-nitro-(323579-94-8)
• EPA Substance Registry System: Benzenemethanol, a-ethenyl-2-nitro-(323579-94-8)

Safety Data

• Hazardous Substances Data: 323579-94-8(Hazardous Substances Data)

Upstream product

• 117298-96-1 (E)-(3-chloroprop-1-enyl)-2-nitrobenzene 
• 552-89-6 2-nitro-benzaldehyde 
• 3536-96-7 vinylmagnesium chloride 
• 1826-67-1 vinyl magnesium bromide 

Downstream Products

• 323579-98-2 1-(2-nitrophenyl)-allyl 4'-nitrophenyl carbonate 
• 849098-20-0 acetic acid 1-(2-nitro-phenyl)-allyl ester 
• 950202-53-6 C₁₈H₁₁N₃O₅ 
• 17408-15-0 1-(2-nitrophenyl)propanone 
• 131470-23-0 1-(2'-aminophenyl)prop-2-en-1-ol 

Relevant articles and documents

Mild Darzens Annulations for the Assembly of Trifluoromethylthiolated (SCF3) Aziridine and Cyclopropane Structures

We report mild new annulation approaches to trisubstituted trifluoromethylthiolated (SCF3) aziridines and cyclopropanes via Darzens inspired protocols. The products of these anionic annulations, rarely studied previously, possess attractive features rendering them valuable building blocks for synthesis platforms. In this study, trisubstituted acetophenone nucleophiles bearing SCF3 and bromine substituents in their α position were shown to undergo [2 + 1] annulations with vinyl ketones and tosyl-protected imines under mild reaction conditions.

Structural Modification of Natural Product Ganomycin i Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo

It is a great challenge to develop drugs for treatment of metabolic syndrome. With ganomycin I as a leading compound, 14 meroterpene derivatives were synthesized and screened for their α-glucosidase and HMG-CoA reductase inhibitory activities. As a result, a α-glucosidase and HMG-CoA reductase dual inhibitor ((R,E)-5-(4-(tert-butyl)phenyl)-3-(4,8-dimethylnona-3,7-dien-1-yl)furan-2(5H)-one, 7d) with improved chemical stability and long-term safety was obtained. Compound 7d showed multiple and strong in vivo efficacies in reducing weight gain, lowering HbAlc level, and improving insulin resistance and lipid dysfunction in both ob/ob and diet-induced obesity (DIO) mice models. Compound 7d was also found to reduce hepatic steatosis in ob/ob model. 16S rRNA gene sequencing, SCFA, and intestinal mucosal barrier function analysis indicated that gut microbiota plays a central and causative role in mediating the multiple efficacies of 7d. Our results demonstrate that 7d is a promising drug candidate for metabolic syndrome.

Study of Intermediates in Iridium-(Phosphoramidite,Olefin)-Catalyzed Enantioselective Allylic Substitution

Experimental mechanistic studies of iridium-catalyzed, enantioselective allylic substitution enabled by (phosphoramidite,olefin) ligands are reported. (η2-Allylic alcohol)iridium(I) and (η3-allyl)iridium(III) complexes were synthesiz